Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib

Table 1

International Prognostic Scoring System.

Variable (1 point each)	Risk group
Age > 65 years	Low risk: 0 points
Constitutional symptoms	Intermediate-1 risk: 1 point
Hemoglobin < 10 g/dL	Intermediate-2 risk: 2 points
Leukocyte count > 25 × 10^9/L	High risk: ≥ 3 points
Circulating blasts ≥ 1%